Long-term evolocumab therapy leads to further reductions in cardiovascular events

Long-term low-density lipoprotein (LDL) cholesterol lowering with evolocumab is safe and well tolerated and leads to further reductions in cardiovascular events compared with shorter treatment, according to late breaking results from the FOURIER open-label extension (OLE) study presented in a Hot Line session on 29 August at ESC Congress 2022. Principal investigator Dr. Michelle O’Donoghue […]

Continue Reading